It's a crowded market for ophthalmological devices, and PowerVision wants to keep a leg up on the competition: As part of a new multicenter clinical study, the company implanted its innovative fluid-based intraocular lens into 10 patients.
Germany's Biotronik said 6-month results from a broader study of a drug-coated balloon to treat leg blood clots showed a major boost in the standard of care compared to standard balloon angioplasty.
Edwards Lifesciences reports initial success with the first three human implants of its Fortis mitral transcatheter heart valve, a necessary milestone if the California company is to succeed in both diversifying and broadening its market-leading presence in the transcatheter valve-replacement space.
Texas devicemaker Kinetic Concepts is touting the results of a new independent study that shows its wound-healing therapy system reduces operating room visits and hospital stays compared to the competition.
Metal fixtures are the norm in surgery--but scientists may have found a safer, more durable way to mend broken bones. A new study shows that silk can be used to secure bone material, providing an alternative to traditional devices.
France's Carmat has another major milestone to report regarding its artificial heart. The first patient implanted with the device has died after surviving for 74 days.
Noninvasive prenatal blood tests are making a market splash--and Illumina's diagnostic might surpass the competition: A new study found that the company's innovative test for Down syndrome and other genetic abnormalities outperforms current screening methods, and reduces false-positive results when compared with traditional testing.
OrbusNeich has enrolled its first patient in a two-country proof-of-concept study for its innovative dual-therapy stent.
While bioresorbable stents are inching their way through the U.S. development process, a newly published German clinical trial involving the first product of its kind to hit the market reinforces the medical benefit of a device that dissolves back into the body when its task is complete.
A leadless pacemaker, approved for use in Europe, has found its way into its first U.S. patient, St. Jude Medical announced Thursday. Dr. Vivek Reddy implanted the Nanostim leadless pacemaker at The Mount Sinai Hospital in New York, starting a pivotal trial for FDA approval.